Vol. 3 No. 11 (2023)
Reimbursement Recommendations

Cabozantinib (Cabometyx)

Published November 27, 2023

Key Messages

  • CADTH recommends that Cabometyx in combination with Opdivo be reimbursed by public drug plans for the treatment of adults with advanced or metastatic renal cell carcinoma (RCC) who have had no prior systemic therapy for metastatic disease if certain conditions are met.
  • Cabometyx in combination with Opdivo should be covered in patients aged 18 years and older with RCC that is not amenable to curative surgery or radiation therapy, or has spread to other organs; who have not received prior cancer treatment targeting the entire body for advanced RCC; and who are in relatively good health (i.e., have good performance status). Cabometyx in combination with Opdivo should not be reimbursed to treat patients who have active tumours in the brain or spinal cord from the cancer spreading or active autoimmune disease.
  • Cabometyx in combination with Opdivo should be reimbursed if prescribed by a clinician with expertise in treating RCC in an outpatient oncology clinic or institution and the total drug cost of Cabometyx in combination with Opdivo does not exceed the total drug cost of the lowest-cost alternative combination regimen.